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Early molecular events related to cytoskeleton are poorly described in Amyotrophic Lateral
Sclerosis (ALS), especially in the Schwann cell (SC), which offers strong trophic support to
motor neurons. Database for Annotation, Visualization and Integrated Discovery (DAVID)
tool identified cytoskeleton-related genes by employing the Cellular Component Ontology
(CCO) in a large gene profiling of lumbar spinal cord and sciatic nerve of presymptomatic
SOD1G93A mice. One and five CCO terms related to cytoskeleton were described from the
spinal cord deregulated genes of 40 days (actin cytoskeleton) and 80 days (microtubule
cytoskeleton, cytoskeleton part, actin cytoskeleton, neurofilament cytoskeleton, and
cytoskeleton) old transgene mice, respectively. Also, four terms were depicted from
the deregulated genes of sciatic nerve of 60 days old transgenes (actin cytoskeleton,
cytoskeleton part, microtubule cytoskeleton and cytoskeleton). Kif1b was the unique
deregulated gene in more than one studied region or presymptomatic age. The expression
of Kif1b [quantitative polymerase chain reaction (qPCR)] elevated in the lumbar spinal cord
(40 days old) and decreased in the sciatic nerve (60 days old) of presymptomatic ALS mice,
results that were in line to microarray findings. Upregulation (24.8 fold) of Kif1b was seen
in laser microdissected enriched immunolabeled motor neurons from the spinal cord of 40
days old presymptomatic SOD1G93A mice. Furthermore, Kif1b was dowregulated in the
sciatic nerve Schwann cells of presymptomatic ALS mice (60 days old) that were enriched
by means of cell microdissection (6.35 fold), cell sorting (3.53 fold), and primary culture
(2.70 fold) technologies. The gene regulation of cytoskeleton molecules is an important
occurrence in motor neurons and Schwann cells in presymptomatic stages of ALS andmay
be relevant in the dying back mechanisms of neuronal death. Furthermore, a differential
regulation of Kif1b in the spinal cord and sciatic nerve cells emerged as key event in ALS.
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INTRODUCTION
Amyotrophic Lateral Sclerosis (ALS) is a progressive, rapid and
fatal neurodegenerative disease that affects motor neurons of the
spinal cord, brainstem, and cerebral cortex (Tripathi and Al-
Chalabi, 2008). The mortality is often due to a respiratory failure
(Shaw et al., 2001).
ALS pathogenesis is still unknown. Nevertheless, the mecha-
nisms underlying neurodegeneration in ALS seem multifactorial
and take place in neurons and non-neuronal cells (Boillee et al.,
2006a,b; Yamanaka et al., 2008;Wang et al., 2013). Recent analyses
have showed the involvement of cytoskeleton, leading a disrup-
tion of intracellular function, and intercellular communication,
with relevance to the triggering of motor neuron death (Guipponi
et al., 2010). In fact, those events are especially important to
motor neurons, highly polarized cells that establish contact with
their target and surrounding Schwann cells through long axons.
The steady bidirectional flux of molecules and organelles in
the motor neuron axons is necessary for cell survival and main-
tenance (Liu et al., 2013; Vinsant et al., 2013). In this context,
cytoskeleton impairments might account for the described ALS
mechanisms as regarding axonal/mitochondrial alteration, sig-
naling endosome dysfunction, protein aggregation and apoptosis
(Boillee et al., 2006a,b; Ferraiuolo et al., 2011; Kiernan et al., 2011;
Usuki et al., 2012).
The presence of Schwann cell-expressing the distress
biomarker ATF-3 in spinal nerves (Malaspina et al., 2010) before
symptom onset suggests the contribution of those cells to ALS
pathogenesis (Keller et al., 2009). Remarkably, axonal retraction
and motor neuron disconnection from neuromuscular joints are
ALS early events (Fischer et al., 2004; Parkhouse et al., 2008) that
seem to be induced by Schwann cell mechanisms (Vinsant et al.,
2013). For instance, distal Schwann cells produce semaphorin 3,
a chemorepellent molecule for terminal axons (De Winter et al.,
2006). Furthermore, the expression of the glial intermediate
filament protein GFAP in Schwann cells of the peripheral nerve
implies a dynamic alteration of cytoskeleton and turnover of
myelin sheath (Hanyu et al., 1982). Moreover, an accumulation of
iNOS immunoreactivity at the paranodal regions of Schwann cell
myelin sheaths of peripheral nerves of presymptomatic ALS mice
gives additional evidence for the impaired paracrine mechanisms
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between motor neuron and Schwann cell (Chen et al., 2010).
Thus, it should be considered that the early peripheral events
related to cytoskeleton of motor neurons and Schwann cells may
contribute to neuronal dying back via disruption of peripheral
neurotrophic stimuli (Keller et al., 2009; Dadon-Nachum et al.,
2011; Gould and Kendall, 2011; Gould and Oppenheim, 2011;
Liu et al., 2013).
As a short lasting disease, the challenge on ALS investigation
is the employment of an adequate experimental model to evalu-
ate presymptomatic mechanisms triggering motor neuron death.
With this regard, it is known that transgene mice expressing
human mutant copper/zinc superoxide dismutase 1 (SOD1G93A)
develop clinical and pathological features similar to those seen in
human ALS and are considered an excellent model to study the
pathogenic mechanisms of the disease (Gama Sosa et al., 2012).
The model is particularly useful to evaluate the events related to
motor neuron degeneration prior neurological symptoms (Alves
et al., 2011).
Large-scale microarray-based gene expression has been try-
ing to identify new molecular cues potentially involved in the
ALS pathogenesis both in animal models and postmortem tissue
(Olsen et al., 2001; Hensley et al., 2002; Yoshihara et al., 2002;
Dangond et al., 2004; Perrin et al., 2005; Ferraiuolo et al., 2007,
2009; Fukada et al., 2007; Lobsiger et al., 2007; Vargas et al., 2008;
Kudo et al., 2010; Boutahar et al., 2011; Cooper-Knock et al.,
2012). However, there is a lack of investigation on the analysis of
cytoskeleton-related gene profiling. The evaluation of deregulated
genes in specific enriched cells obtained by in vitro purification,
single cell laser microdissection or cell sorting might contribute
to refine the alterations of gene expression-related to cytoskele-
ton molecules on specific cells of peripheral motor neuron
unit.
By means of a high-density oligonucleotide microarray-linked
to specific tools capable to identify cellular components, the aim
of this work was to identify the regulation of cytoskeleton-related
genes in the presymptomatic stage in the spinal cord and sciatic
nerve of the SOD1G93A mouse model. The work has also evalu-
ated the modulation of Kif1b in the enriched spinal cord motor
neurons and sciatic nerve Schwann cells.
MATERIALS AND METHODS
ANIMAL AND TISSUE SAMPLE
Transgene SOD1G93A mice (The Jackson Laboratory, Bar Harbor,
ME, USA) were crossbred and the colony was maintained in
a specific pathogen-free environment of the animal facility of
University of São Paulo Medical School (São Paulo, Brazil) as
described previously (Gurney, 1994; Scorisa et al., 2010; Alves
et al., 2011). Animals were kept under controlled temperature and
humidity conditions with a standardized light–dark cycle (lights
on at 7.00 a.m. and off at 7.00 p.m.) and free access to food
pellets and tap water. Mice were genotyped by PCR amplifica-
tion of DNA extracted from their tails in order to identify the
SOD1 mutation (Gurney, 1994; Scorisa et al., 2010; Alves et al.,
2011). The study was conducted under protocols approved by the
Animal Care and Use of Ethic Committee at University of São
Paulo and in accordance to the Guide for the Care and Use of
Laboratory Animals adopted by the National Institutes of Health.
Forty, 60, and 80 days old presymptomatic specific pathogen-
free male SOD1G93A mice and their age-paired wild-type controls
(20–25 g body weight) were used in the experiments. No motor
neuron death was seen in those animal ages (Alves et al., 2011)
so that they were chosen for the present presymptomatic anal-
yses. Animals were killed by decapitation. Lumbar spinal cords
(40 and 80 days old mice) and sciatic nerves (60 days old mice)
were removed, frozen, and stored at −80◦C until use. Four-five
animals per group were used in the microarray experiments. The
quantitative polymerase chain reaction (qPCR) analyses of lum-
bar spinal cords (40 days old mice), and sciatic nerves (60 days
old mice) as well as of enriched cells samples (60 days old mice)
employed four mice of each transgene and wild-type groups.
RNA ISOLATION AND MICROARRAY EXPERIMENTS
The procedures of microarray experiments and statistical anal-
ysis of the mouse spinal cords were described in our previ-
ous publication which has employed a Whole Mouse Genome
Oligo 4 × 44 K microarray platform (Agilent Technologies, USA)
(De Oliveira et al., 2013). Regarding the sciatic nerve samples,
total RNA was isolated using the Miniprep kit (Zymo, USA).
The procedure was performed according to the manufacturer’s
instructions. The quantity and integrity of RNA were determined
by spectrophotometer (Nanodrop, Thermo Scientific, USA) and
microfluidics-based electrophoresis (Agilent 2100 Bioanalyzer,
Agilent Technologies, USA), respectively. RNA samples with OD
260/280 of approximately 2.0 and RIN >7.0 were used for
microarray experiments and qPCR. A pool of RNAs from neona-
tal organs (heart, kidney, liver) was used as reference sample.
A representative electropherogram from Bioanalyzer evaluation
of RNA integrity of the sciatic nerve samples is shown in the
supplementary material (Figure S1).
In the case of sciatic nerve analysis, RNAs of samples (25 ng)
and reference (100 ng) were reverse transcribed by the Low-input
RNA Linear Amplification kit and then transcribed to Cy3-
labelled (samples) or Cy5-labelled (reference) according to the
manufacturer’s instructions (Agilent Technologies, USA) and to
previous descriptions (De Oliveira et al., 2013, 2014).
A total of 300 ng of Cy3-labelled cRNAwas hybridized together
with the same amount of Cy5-labelled reference to Whole Mouse
Genome Oligo 8 × 60 K. After an overnight hybridization at
65◦C, the slides were washed and treated with a Stabilizing
and Drying Solution (Agilent Technologies, USA) and scanned
(AgilentMicroarray Scanner). All steps were performed according
to the manufacturer’s instructions (Agilent Technologies, USA).
The raw data from hybridizations and experimental conditions
are available on the Gene Expression Omnibus website under
accession numbers GSE50642 (spinal cord analysis, according to
De Oliveira et al., 2013) and GSE56926 (sciatic nerve analysis).
MICROARRAY ANALYSIS
Raw image data were converted to numerical data using the
Agilent Feature Extraction Software, version 9.1.3.1 (spinal cord)
(De Oliveira et al., 2013) and version 11.0.1.1 (sciatic nerve).
Microarrays without enough quality were taken out from fur-
ther analyses, and the study proceeded with four samples for each
group in the both studied regions. As already described for spinal
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cord in our previous study (De Oliveira et al., 2013), sciatic nerve
microarray raw data (.txt files) were transferred to R v. 3.0.1 soft-
ware (Team RDC, 2012) and analyzed with the Bioconductor
(Gentleman et al., 2004) package limma (Smyth, 2005). Finally,
the probes were tested for differential expression using a lin-
ear model followed by Bayes moderated t-test (Smyth, 2005) for
the comparisons of interest. P-values < 0.05 were accepted as
differentially expressed genes.
COMPLEMENTARY DNA MICROARRAY DATA ANALYSIS
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7b functional tool (http://david.abcc.
ncifcrf.gov/) (Huang Da et al., 2008) was used to identify genes
related to cytoskeleton through the Gene Ontology (GO) annota-
tion database. DAVID analysis focused in the Cellular Component
Ontology (CCO). The analysis was conducted on the lists con-
taining the up-regulated and down-regulated genes for each
experimental group. High stringency (EASE score set to 0.05)
parameters were selected to improve confidence on the terms
to be pointed as enriched. Cellular component terms related to
cytoskeleton gene lists were then organized. The BioVenn tool
(http://www.cmbi.ru.nl/cdd/biovenn/) (Hulsen et al., 2008) was
used to identify common and exclusively expressed genes between
groups.
LASER CAPTURE MICRODISSECTION OF MOTOR NEURONS FROM
SPINAL CORD
Immunolabeled motor neurons of lumbar mouse spinal cord
(SOD1G93A and wild-type groups) were microdissected as
described previously (De Oliveira et al., 2009, 2013). Spinal
cord sections were rinsed for 3min in phosphate buffered
saline (PBS) containing 3% Triton X-100 (Sigma, USA) and
then incubated overnight with a polyclonal goat anti-choline
acetyltransferase (ChAT, 1:100; Abcam, USA) diluted in 0.3%
Triton X-100 containing 1% bovine serum albumin (BSA;
Sigma, USA), 1mM dithiothreitol (DTT; Invitrogen, CAN), and
0.1U/μl RNAse inhibitor (Invitrogen, CAN). Sections were then
washed in PBS (3 × 15 s) and then incubated for 1 h in the
dark and at room temperature with an Alexa 594-conjugated
donkey anti-goat antibody (Invitrogen, USA) diluted (1:100)
in the solution described above. Sections were rinsed care-
fully three times with PBS for 15 s and immediately submit-
ted to single cell laser microdissection procedures. The ChAT
immunofluorescence profiles for specific identification of motor
neurons in the microdissection procedure are illustrated in
Figures 1A,B.
About 100 motor neurons were isolated from each lumbar
spinal cord using P.A.L.M. Microlaser Technologies (Zeiss). RNA
was extracted from the microdissected motor neurons using the
PicoPure RNA isolation kit (Arcturus, USA). Linear amplifica-
tion of RNA was performed following Eberwine’s procedure (Van
Gelder et al., 1990) using the RiboampHSplus kit (Arcturus, USA)
according to the manufacturer’s protocol. The quantity and qual-
ity of the amplified RNA were analyzed as described above. Laser
microdissected motor neuron samples were submitted to PCRs
for verification of sample enrichment and the results are shown
in the supplementary material (Figure S2).
FIGURE 1 | Photomicrographs illustrating motor neuron (A,B) and
Schwann cell (C,D) laser microdissection process. The quick ChAT and
S100β immunofluorescence procedures allow recognizing the motor
neuron (A,B) and Schwann cell (C,D) profiles (arrows). Profiles were then
selected for microdissection (A,C). After laser firing and microdissection,
selected cell profiles (arrows) can no longer be visualized in the tissue
(B,D). Scale bars: 20μm.
LASER CAPTURE MICRODISSECTION OF SCHWANN CELLS FROM
SCIATIC NERVE
Sciatic nerve of 60 days old mice (SOD1G93A and wild-type
groups) were rapidly removed and frozen in ice cold isopentane
at −45◦C and stored at −80◦C until use. The labeling procedure
was performed according to adaptation of a previous description
(DeOliveira et al., 2009, 2013). Taw-mountedmouse sciatic nerve
sections (5μm) were rapidly defrosted for 30 s and fixed with
ice-cold acetone, for 3min. Sections were then rinsed (3min)
in PBS containing 3% Triton X-100 and incubated with a poly-
clonal rabbit anti-S100β antibody (1:200; Dako, USA) diluted in
PBS containing 0.3% Triton X-100 (Sigma, USA) and 1% BSA
(Sigma, USA) for 5min. Sections were washed in PBS (3 × 15 s)
and then incubated (5min) in the dark and at room tem-
perature with a texas red-conjugated goat anti-rabbit antibody
(Jackson ImmunoResearch Laboratories, USA) diluted (1:50) in
the solution described above. Sections were then rinsed care-
fully three times with PBS for 15 s and immediately submitted to
single cell laser microdissection procedures. Schwann cell S100β
immunofluorescence profiles identified in the microdissection
procedure are illustrated in Figures 1C,D.
About 200 Schwann cells were isolated from each sciatic
nerve using the P.A.L.M. Microlaser Technologies. The RNA
was extracted from the cells and amplified as described above.
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The quantity and quality of amplified RNA were analyzed as
described above. Laser microdissected Schwann cell profiles were
also submitted to PCRs for verification of sample enrichment.
The detailed protocol and results are shown in the supplementary
material (Figure S3).
FLOW CYTOMETRY SORTING SCHWANN CELLS
Schwann cells were isolated by means of flow cytometry sorting
from the sciatic nerve explants of 60 days old SOD1G93A mice
and their age-paired wild-type controls. Briefly, animals were
deeply anaesthetized with sodium pentobarbital 3% (100mg/kg,
ip) and their sciatic nerves were dissected under aseptic con-
ditions. Nerves were then placed in 60mm dishes containing
Leibovitz-15 medium (Gibco, USA), divested of their epineurial
sheaths and chopped into 1mm pieces. The fragments were
then transferred to new 60mm dishes containing D-10 cul-
ture medium [composed by DMEM (Gibco, USA) supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin
(Sigma, USA)] and were maintained there in 5% CO2 at 37◦C
for 5 days. The sciatic nerve fragments were then transferred to
30mm dishes containing 2.5ml Hanks’ Balanced Salt solution
(Sigma, USA), 0.05% trypsin (Gibco, USA), and 1mg colla-
genase (Worthington, USA). The fragments were kept in that
solution for 2 h in 5% CO2 at 37◦C. Tissue fragments were
washed with D-10 and dissociated by trituration through a
200μl-pipette and a 19-gauge sterile needle. The suspension
was centrifuged at 1500 rpm for 5min at 4◦C and the cells
were resuspended in D-10 medium. This step was repeated and
cells were passed through a 70μm-cell strainer (BD Bioscience,
USA).
The cells were centrifuged at 1,500 rpm for 5min at 4◦C
and the pellets were resuspended in PBS containing 10% fetal
bovine serum and 0.01% sodium azide, (Sigma, USA). Sciatic
nerve-derived cell suspension was incubated with a fluorescein
isothiocyanate (FITC)-conjugated mouse p75NGF receptor anti-
body (Abcam, USA) diluted in the buffer solution (1/200) for
1 h at room temperature as mentioned above. The p75NGF
receptor labeling was employed in the cell sorting experiments
because it is a well-characterized surface marker for Schwann
cells (Niapour et al., 2010). The samples were then centrifuged
(300 × g for 5min at 4◦C). The pellets were washed two times
and resuspended in the PBS described above (500μl). Cells were
then analyzed for type and specificity as well as separated on a
FACSAria III Cell Sorter (BD Biosciences, USA). A maximum of
106 cells were resuspended in 500μl of buffer. Flow cytometry
dot plot Schwann cell profiles are shown in Figure 2. Details of
flow cytometry procedures for cell specificity are described in the
supplementary material (Figure S4).
RNA of enriched cells was extracted using Trizol (Life
Technologies, USA) according to the manufacturer’s protocol.
The quantity (NanoDrop 1000 Spectrophotometer) and quality
(Agilent 2100 bioanalyser, RNA 6000 Pico LabChip) of RNA were
analyzed as described above. Also, the Schwann cell samples were
submitted to PCRs in order to access contamination from other
cell types. Protocol and results regarding specificity of separated
Schwann cell samples are presented in the supplementarymaterial
(Figures S3).
PRIMARY SCHWANN CELL CULTURE
Highly purified Schwann cell cultures were obtained from sciatic
nerve explants taken from 60 days old SOD1G93A and wild-type
mice as described above. Nerve pieces were transferred weekly to
new 60mm dishes filled with 1ml of D-10 for 5 weeks. Dishes
were replaced every other day with a fresh medium (Oudega
et al., 1997). After that period, explants were replated onto 35mm
dishes containing a solution of 1.25U/ml dispase (Boehringer
Mannheim, Germany), 0.05% collagenase (Worthington, USA),
and D-10, and were kept under overnight incubation in 5% CO2
at 37◦C. Following, explants were washed in D-10 and dissoci-
ated. The resulting cells were treated with a Thy1.2 antibody (BD
Bioscience, USA) and a rabbit serum complement (Calbiochem,
USA) for 30min at room temperature for fibroblast elimina-
tion. The protocol for cell enrichment was described elsewhere
(Brockes et al., 1979; White et al., 1983; Dong et al., 1999)
and was modified according to our experience. The obtained
Schwann cells were then seeded onto laminin (Sigma, USA)
coated 100mm dishes for expansion. Twenty-four hours later,
the culture medium was replaced by a D-10 medium supple-
mented with 2mM forskolin (Sigma, USA) and 20mg/ml pitu-
itary extract (Gibco, USA). Cells were allowed to expand in that
medium until confluence has reached. The medium was changed
every other day in the expansion period. The cells of the third pas-
sage were used for experiments. Samples of the primary Schwann
cell cultures were fixed and immunostained with S100β antibody
and nuclei were stained with diamidino-2-phenylindole (DAPI)
for cell type verification, as showed in Figure 3.
Schwann cell total RNA was extracted using Trizol (Life
Technologies) according to the manufacturer’s protocol. The
quantity (NanoDrop 1000 Spectrophotometer) and quality
(Agilent 2100 bioanalyser, RNA 6000 Pico LabChip) of RNA were
analyzed as described above. Cultured Schwann cell RNA samples
were submitted to PCRs in order to access fibroblast contami-
nation; the protocol and results are shown in the supplementary
material (Figure S3).
QUANTITATIVE PCR
Microarray analyses identified the differentially expressedKif1b in
the spinal cord (40 days old mice) and sciatic nerve (60 days old
mice) and it was the only gene that its product has been described
in the context of ALS (Conforti et al., 2003; Pantelidou et al.,
2007). The gene was then selected for verification by qPCR in the
whole spinal cord (40 days old mice) and sciatic nerve (60 days)
as well as in the enriched motor neurons and Schwann cells. The
qPCR verification was performed on independent samples.
Spinal cord cDNA was synthesized from DNAse-treated 1μg
total RNA by employing a TaqMan reverse transcription kit
(Applied Biosystems, USA). Sciatic nerve cDNA was synthe-
sized from 100 ng of total RNA by using a Maxima First Strand
cDNA Synthesis Kit (Thermo Scientific, USA) according to
manufacturers.
qPCR reactions were carried out in duplicate by means of the
PikoReal-Time PCR System (Thermo Scientific, USA) employing
40 ng cDNA for spinal cord and 15 ng cDNA for sciatic nerve, the
DyNAmo ColorFlash SYBR Green qPCR kit (Thermo Scientific,
USA) and finally 400 nM of each primer (Kif1b—Forward 5′-3′:
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FIGURE 2 | Flow cytometry analysis of Schwann cells from a
mouse sciatic nerve employed in the experiments. Dot plots
indicate the total number of events in the sciatic nerve cell
suspension and the dots inside the red box represent the
excluded doublet and dead profiles, which have been eliminated
by morphological criteria according to previous descriptions (Shapiro,
2005; Herzenberg et al., 2006) (A). Dot plots of unspecific
fluorescence are shown in (B). FITIC-conjugated p75NGF receptor
antibody was employed in the immunolabeling of Schwann cells (C,D).
After morphological criteria, dot plots of labeling profiles (B) were
identified as unspecific and specific profiles (red boxes) (C). Specific
profiles-based on morphological criteria were further analyzed in
relation to fluoresce criteria (B) and the specific p75NGF receptor
positive Schwann cells profiles were identified [red box in (D)].
CTGCTAGCCCTTTAAGACTCG; Reverse 5′-3′: AAACTCCTAG
ACAAACGCTCC; Gapdh—Forward 5′-3′: GAGTAAGAAACC
CTGGACCAC; Reverse 5′-3′: TCTGGGATGGAAATTGTGAGG)
in a 20μl final volume reaction.
The Kif1b expression was also evaluated in the enriched
microdissected Schwann cells and motor neurons as well as in
the Schwann cells enriched by means of cell sorting and primary
culture procedures. cDNA samples of microdissected cells and
of cultured Schwann cells were synthesized from 1μg of ampli-
fied RNA as described previously (De Oliveira et al., 2013). The
cDNA of flow cytometry sorting Schwann cells was synthesized
from 100 ng of total RNA.
The cycling for SYBR reactions was composed by an initial
denaturation at 95◦C for 10min. Templates were amplified by
40 cycles of 95◦C for 15 s and of 60◦C for 30 s. A dissociation
curve was then generated to ensure amplification of a single
product and absence of primer dimers. A standard curve was gen-
erated for each primer pair in order to determine the efficiency of
the PCR reaction over a range of template concentrations from
0.032 to 20 ng/μl, using cDNA synthesized from reference mouse
RNA. The efficiency for each set of primers was 100 ± 5%. Gene
expressions, which were normalized by Gapdh, could be deter-
mined using the Ct mathematical model (ABI PRISM 7700
Sequence Detection System protocol; Applied Biosystems).Gapdh
was chosen as a housekeeping gene to normalize the qPCR values
because the microarray analysis showed no alteration in the gene
expression across samples.
STATISTICAL ANALYSIS
The statistical method employed in the microarray analysis is
described above (Hulsen et al., 2008). Furthermore, one-tailed
unpaired t-test was used to determine the statistical significance
of differences in gene expression [Graphpad Prism 5 (San Diego,
CA)] in the qPCR analyses.
RESULTS
MICROARRAY ANALYSIS
The DAVID analysis of differentially expressed genes of 40 days
old SOD1G93A mice pointed 34 enriched GO terms under high
stringency conditions. The CCO indicated only one GO term
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FIGURE 3 | Microphotographs of Schwann cell cultures obtained from
sciatic nerve of a 60 days old SOD1G93A mouse. Non-purified (A,B)
and Thy1.2 antibody/rabbit serum complement-eliminated fibroblast
[purified, (C)] Schwann cell cultures are shown under phase-contrast (A)
and immunofluorescence (B,C) microscopy. Cultured Schwann cells were
evidenced by means of S100 immunofluorescence (greenish color), and
the cell nuclei (bluish color) were stained by DAPI (B,C). The different
morphology of Schwann cells (arrowhead) and fibroblasts (arrow) is
observed (A). S100 positive immature Schwann cells (arrow) and DAPI
positive nuclei of cells lacking cytoplasmic S100 labeling (arrowhead) are
seen in a 24 h plating non-purified culture (B). Vast majority of S100
immunolabeled Schwann cells possess a homogeneous morphology in a
7-days purified culture after fibroblast elimination [arrow, (C)]. Scale bars:
50μm.
related to cytoskeleton, the actin cytoskeleton, with 14 genes
(six down and eight upregulated), which are shown in Table 1.
DAVID also pointed 63 enriched terms from the differentially
expressed genes of spinal cord of 80 days old SOD1G93A mice
(Table 2). The CCO indicated five GO terms related to cytoskele-
ton (Table 2) in the spinal cord of 80 days old SOD1G93A mice,
specifically the microtubule cytoskeleton (35 genes), cytoskele-
ton part (53 genes), actin cytoskeleton (16 genes), neurofilament
cytoskeleton (three genes), and cytoskeleton (76 genes). Those
genes are overlapped with the 76 deregulated genes of cytoskele-
ton category (25 down and 51 upregulated).
The DAVID analysis also pointed 55 enriched terms
from the deregulated genes of sciatic nerve of 60 days old
SOD1G93A mice. Furthermore, the CCO indicated four GO
terms related with cytoskeleton, specifically the actin cytoskeleton
(43 genes), cytoskeleton part (101 genes), microtubule cytoskele-
ton (64 genes), and cytoskeleton (146 genes). The 146 genes of
the cytoskeleton GO term (74 down and 72 upregulated) are
overlapped with all other GO terms (Table 3).
From the above lists of differentially expressed genes related
to cytoskeleton pointed by CCO, nine genes (Dync1li2, Kif1b,
Kif1c, Lcp1, Lima1, Myh11, Myo1c, Srcin, Twf1) were deregulated
in both spinal cord and sciatic nerve of SOD1G93A mice at the
presymptomatic ages 40 and 60 days, respectively, and 10 genes
(Abl1, Calm3, Clic5, Dynll2, Krt7, Myl4, Myo1d, Ncs1, Pdlim2,
Strbp) were deregulated in the above regions of 80 and 60 days
mice, respectively, as shown by the Venn diagram (Figure 4).
Furthermore, only the Maea was seen differentially expressed in
the spinal cord of 40 and 80 days old presymptomatic SOD1G93A
mice and no gene appeared to repeat in the three lists of the stud-
ied regions of the presymptomatic mice (Figure 4). It should be
pointed out that only the Kif1b from the above described differ-
entially expressed genes related to cytoskeleton has been already
mentioned in the context of ALS and has been detailed in the
present cellular and molecular analyses.
MOTOR NEURON AND SCHWANN CELL ENRICHMENT
In order to analyze the modulation of gene expression in specific
cell populations possibly involved in the pathogenic mechanisms
in ALS, spinal cord motor neurons (lumbar regions) were
obtained by means of single cell laser microdissection and the
sciatic nerve Schwann cells were achieved by means of laser
microdissection, flow cytometry cell sorting and cell culture. The
levels of cDNA specific cell type marker that demonstrated the
enrichment for each cell type obtained by respective technique
are shown in the Supplementary Material (S2, S3).
Kif1b REGULATION EVIDENCED BY qPCR
qPCR analyses of Kif1b expression showed an upregulation (1.21
fold) of the gene in spinal cord of presymptomatic 40 days old
SOD1G93A mice (Figure 5A) and a downregulation (1.57 fold) in
the sciatic nerve of presymptomatic 60 days old transgene mice
(Figure 5B). These regulations were coincident and supported
themicroarray findings. Additionally, qPCR analyses also demon-
strated the differentially expression of Kif1b in enriched cell assays
using two cycle amplified RNA. Upregulation of Kif1b (24.8 fold)
was seen in laser microdissected motor neurons from 40 days
old SOD1G93A mice (Figure 5C); this regulation was in the same
direction to that found in the whole spinal cord preparation of
40 days transgene mice by means of microarray and qPCR analy-
ses. Remarkably, Kif1b was downregulated in the enriched sciatic
nerve Schwann cells (60 days old SOD1G93A mice) by means
of single cell laser microdissection (6.35 fold), cell sorting (3.53
fold), and cell culture (2.70 fold) (Figure 5D), regulations that
were in the same direction to that found in the whole sciatic nerve
preparation of 60 days transgene mice by means of microarray
and qPCR analyses.
DISCUSSION
CYTOSKELETON ENRICHMENT ANALYSIS OF GENE PROFILING IN
PRESYMPTOMATIC ALS
Gene regulation of cytoskeleton-related molecules employing
microarray technology has been described in the spinal cord
and/or microdissected survival neurons from post mortem mate-
rial of ALS patients (Jiang et al., 2005; Offen et al., 2009; Cox
et al., 2010; Tanaka et al., 2012), thus reflecting the cytoskele-
ton responses to injury instead its role on neurodegenerative
triggering. Sporadic and unsystematic results on deregulated
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Table 1 | List of differentially expressed genes in spinal cord of 40 days old SOD1G93A mice related to cytoskeleton.
Probe set ID Gene symbol Gene name Fold change
A_52_P654108 Dync1li2 dynein, cytoplasmic 1, light intermediate chain 2 1.11
A_51_P319551 Kif3a kinesin family member 3A −1.13
A_51_P264956 Kif1b kinesin family member 1B 1.09
A_51_P438349 Kif1c kinesin family member 1C 1.14
A_52_P581390 Kif1c kinesin family member 1C 1.08
A_52_P56751 Lcp1 lymphocyte cytosolic protein 1 −1.14
A_51_P316103 Lima1 LIM domain and actin binding 1 −1.16
A_52_P274238 Maea macrophage erythroblast attacher 1.10
A_51_P362429 Myh11 myosin, heavy polypeptide 11, smooth muscle −1.12
A_52_P241519 Myo1c similar to nuclear myosin I beta; myosin IC −1.15
A_51_P185141 Myo1e myosin IE 1.08
A_51_P440923 Sh3pxd2a SH3 and PX domains 2A; similar to Fish −1.19
A_52_P155100 Srcin1 P140 gene 1.29
A_51_P436534 Twf1 twinfilin, actin-binding protein, homolog 1 (Drosophila) 1.10
A_52_P96782 Wasl Wiskott-Aldrich syndrome-like (human) 1.16
The Kif1c has been demonstrated in the list by two different Probes Set IDs.
genes-related to cytoskeleton in ALS animal models have been
demonstrated in several stages of the disease (Perrin et al., 2005;
Tanaka et al., 2006; Ferraiuolo et al., 2007; Guipponi et al.,
2010; Kudo et al., 2010). The present study extends previous
descriptions by detailing gene profiling in expanded categories
of cytoskeleton-related genes in the presymptomatic ages of the
ALS mouse model. The DAVID analysis was applied by using the
full lists of deregulated genes of the spinal cord of 40 and 80 days
old presymptomatic ALS mice we have published recently (De
Oliveira et al., 2013). Our study has also demonstrated for the first
time the gene profiling of cytoskeleton category in the periph-
eral nerve (sciatic nerve) of the ALS model in a presymptomatic
period of the disease.
It should be highlighted the large number of deregulated
genes of the cytoskeleton-related category in the spinal cord
of presymptomatic ALS mouse of the present study compared
to previous descriptions that employed different methodolo-
gies (Ferraiuolo et al., 2007; Guipponi et al., 2010; Kudo et al.,
2010). In fact, from 13 deregulated genes grouped in categories
of cytoskeleton and transport described in the presymptomatic
spinal cord of a late onset ALS animal model (Guipponi et al.,
2010), the down regulation of kinesin light chain 2 (Klc2) gene
was in agreement to our analysis. Also, from 11 deregulated genes
of the cytoskeleton and motor activity categories described in
microdissected toluidine blue-labeled neurons from the spinal
cord of asymptomatic SOD1G93A mice (Ferraiuolo et al., 2007),
the upregulated Kif1b and Gsn were found, respectively, in spinal
cord of 40 and 80 days oldmice of our analysis. Furthermore, sim-
ilar study that employed a categorization of enriched pathways in
asymptomatic ALS mice has not identified cytoskeleton category
but pointed six differentially expressed cytoskeleton genes (Kudo
et al., 2010).
It is interesting the robust regulation of gene expression
in the spinal cord of the ALS mouse model in the presymp-
tomatic phases of the disease, thus underlining the early events on
modulation of cytoskeleton elements before the death of spinal
cord motor neurons. The genes of cellular components related
to cytoskeleton pointed by DAVID enriched analysis showed 14
and 76 deregulated genes in the spinal cord of 40 and 80 days old
presymptomatic animals respectively, and 146 deregulated genes
in the sciatic nerve of 60 days presymptomatic ALS mice.
In fact, early events regarding impairment of axonal transport,
cytoplasm aggregation and neurite/axonal abnormalities have
been described before the onset of ALS symptoms (Warita et al.,
1999; Williamson and Cleveland, 1999; Magrane and Manfredi,
2009; Rothstein, 2009) and might contribute to the triggering
of motor neuron death. Additional novelty of the present anal-
ysis was the demonstration of deregulated transcripts-related to
cytoskeleton by DAVID categorization in the sciatic nerve of the
presymptomatic ALS mice. Gene profiling in the sciatic nerve
accounts for axonal (minority) and Schwann cell (majority) tran-
scripts (Baraban et al., 2013; Malmqvist et al., 2014), thus adding
an important contribution to molecular analysis on dying back
hypothesis of ALS pathology (Dadon-Nachum et al., 2011; De
Oliveira et al., 2014).
Despite the evidence of protein synthesis in growing or regen-
erating axons in vitro and of mRNA axonal transport and local
translation in developing zebrafish (Baraban et al., 2013), it is
still not clear whether axons of adult motor neurons contain
ribosomes and other elements that are necessary for protein
translation (Jablonka et al., 2004). Altogether, this manuscript
highlights the importance to evaluate the cytoskeleton changes
in the Schwann cells in the still poorly described peripheral
pathology in ALS (Xiao et al., 2006) and their contribution to
impair paracrine trophic actions to motor neurons (unpublished
results from our laboratory, presented as an abstract form in
the 2013 Society for Neuroscience Meting, San Diego, USA). In
order to address this issue, we have developed and presented
here different methods to enrich specific cell types for molecular
analysis.
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Table 2 | List of differentially expressed genes in spinal cord of 80 days old SOD1G93A mice related to cytoskeleton.
Probe set ID Gene symbol Gene name Fold change
A_52_P485007 Abca2 ATP-binding cassette, sub-family A (ABC1), member 2 1.23
A_52_P209101 Abl1 c-abl oncogene 1, receptor tyrosine kinase 1.09
A_52_P72237 Actg1 predicted gene 8543; actin-like 8; predicted gene 7505 1.34
A_51_P188845 Adora1 adenosine A1 receptor 1.15
A_52_P418014 Akt1 thymoma viral proto-oncogene 1 −1.09
A_51_P269375 Ank1 ankyrin 1, erythroid; hypothetical protein LOC100046690 1.13
A_51_P319562 Ank2 ankyrin 2, brain −1.26
A_51_P318104 App amyloid beta (A4) precursor protein −1.16
A_52_P58041 Arpc5 predicted gene 16372; actin related protein 2/3 complex, subunit 5 1.18
A_52_P1157979 Calm3 predicted gene 7743; calmodulin 3; calmodulin 2; calmodulin 1 1.45
A_51_P440682 Cap1 CAP, adenylate cyclase-associated protein 1 (yeast) −1.39
A_51_P135423 Capzb capping protein (actin filament) muscle Z-line, beta 1.15
A_51_P180629 Cdc42ep1 CDC42 effector protein (Rho GTPase binding) 1 1.14
A_51_P128148 Chmp1a chromatin modifying protein 1A; predicted gene 8515 1.34
A_52_P479539 Cit citron 1.37
A_51_P420547 Clic5 chloride intracellular channel 5 −1.13
A_52_P326214 Cttn cortactin; predicted gene 8786 1.25
A_51_P483908 Dctn1 dynactin 1 1.26
A_51_P219868 Dnm1 dynamin 1 1.16
A_51_P448458 Dnm3 dynamin 3 −1.25
A_52_P184304 Dst dystonin; hypothetical protein LOC100047109 1.15
A_52_P429909 Dynll2 dynein light chain LC8-type 2 1.23
A_51_P227962 Dynlrb2 dynein light chain roadblock-type 2 −1.09
A_52_P371946 Eif6 eukaryotic translation initiation factor 6 1.14
A_51_P184806 Elmod2 ELMO domain containing 2 −1.12
A_51_P360622 Elmod3 ELMO/CED-12 domain containing 3 1.10
A_52_P396917 Eml5 echinoderm microtubule associated protein like 5 −1.12
A_52_P524426 Epb4.1l1 erythrocyte protein band 4.1-like 1 1.15
A_52_P621940 Epb4.1l2 erythrocyte protein band 4.1-like 2 1.16
A_52_P684050 Fam110a family with sequence similarity 110, member A −1.23
A_52_P27871 Fnbp1 formin binding protein 1 1.20
A_51_P304757 Gabarapl1 gamma-aminobutyric acid (GABA) A receptor-associated protein-like 1 1.49
A_51_P241465 Gsn gelsolin 1.24
A_52_P212597 Hook1 hook homolog 1 (Drosophila) −1.15
A_52_P247513 Hook3 hook homolog 3 (Drosophila) −1.17
A_52_P49378 Kif1a kinesin family member 1A 1.24
A_52_P282500 Kif21b kinesin family member 21B 1.20
A_51_P193011 Klc1 kinesin light chain 1 1.26
A_51_P363396 Klc2 kinesin light chain 2 1.24
A_51_P259118 Klhl1 kelch-like 1 (Drosophila) −1.32
A_51_P312348 Krt7 keratin 7 −1.14
A_51_P242399 Krt8 keratin 8 −1.13
A_52_P419298 Lasp1 LIM and SH3 protein 1 1.19
A_51_P386638 Llgl1 lethal giant larvae homolog 1 (Drosophila) 1.19
A_51_P411645 Maea macrophage erythroblast attacher 1.19
A_51_P126177 Map1lc3b microtubule-associated protein 1 light chain 3 beta 1.16
A_52_P327537 Mpdz multiple PDZ domain protein 1.16
A_51_P318580 Myh14 myosin, heavy polypeptide 14 1.18
A_51_P512210 Myh6 myosin, heavy polypeptide 6, cardiac muscle, alpha −1.16
A_52_P544523 Myl4 myosin, light polypeptide 4 −1.13
A_52_P650855 Myo1d myosin ID 1.22
A_51_P114062 Ncs1 frequenin homolog (Drosophila) 1.14
(Continued)
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Table 2 | Continued
Probe set ID Gene symbol Gene name Fold change
A_51_P145220 Nefm neurofilament, medium polypeptide 1.30
A_51_P238933 Nudc nuclear distribution gene C homolog (Aspergillus) −1.13
A_52_P89425 Pcnt pericentrin (kendrin) 1.13
A_51_P472726 Pdlim2 PDZ and LIM domain 2 1.31
A_51_P270478 Pin4 protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting, 4
(parvulin)
−1.16
A_52_P359381 Ptk2 PTK2 protein tyrosine kinase 2 1.12
A_51_P275679 Rassf5 Ras association (RalGDS/AF-6) domain family member 5 1.14
A_52_P24320 Rpgrip1l Rpgrip1-like −1.13
A_52_P656024 Sirt2 sirtuin 2 (silent mating type information regulation 2, homolog) 1.19
A_51_P371311 Slc1a4 solute carrier family 1 (glutamate/neutral amino acid transporter),
member 4
1.13
A_51_P495641 Stmn1 stathmin 1; predicted gene 11223; predicted gene 6393 1.14
A_51_P264634 Strbp spermatid perinuclear RNA binding protein 1.15
A_51_P404875 Synm synemin, intermediate filament protein 1.15
A_52_P261322 Tanc1 tetratricopeptide repeat, ankyrin repeat, and coiled-coil containing 1 1.13
A_51_P224843 Tmsb4x thymosin, beta 4, X chromosome; similar to thymosin beta-4 −1.21
A_51_P507899 Ttc8 tetratricopeptide repeat domain 8 −1.10
A_51_P169745 Tuba1a predicted gene 7172; similar to tubulin, alpha 1; tubulin, alpha 1A 1.25
A_52_P490023 Tubb2a tubulin, beta 2A 1.19
A_52_P621603 Tubb2a tubulin, beta 2A 1.26
A_52_P97417 Tubgcp5 tubulin, gamma complex associated protein 5 −1.10
A_52_P266540 Ubr4 ubiquitin protein ligase E3 component n-recognin 4 1.17
A_52_P569218 Utrn utrophin −1.10
A_51_P361788 Vapa vesicle-associated membrane protein, associated protein A −1.10
A_52_P219314 Vasp vasodilator-stimulated phosphoprotein 1.08
A_51_P473252 Zyx zyxin 1.15
The Tubb2a has been demonstrated in the list by two different Probes Set IDs.
DEREGULATED GENES OF CYTOSKELETON MOLECULES ALREADY
POINTED IN ALS
The description of 14 differentially expressed genes (six down and
eight upregulated) in the spinal cord of 40 days old presymp-
tomatic ALS mice already indicates a very early presymptomatic
event related to cytoskeleton with a possible implication to phys-
iopathological mechanisms of the disease onset. From those
genes, only Kif3a and Kif1b or related molecules have been stud-
ied in the context of kinesin dysfunction or impaired anterograde
transport of cargos, like neurofilament, in ALS (Dupuis et al.,
2000; Conforti et al., 2003; Pantelidou et al., 2007). The Kif3a
(downregulation) and Kif1b (upregulation) deregulated genes
seen in the spinal cord of 40 days old SOD1G93A mice were in
line with descriptions of reduction KIF3Aβ in motor cortices of
ALS human and animal model (Pantelidou et al., 2007) and of
KIF3-associated proteins in ALS rodents (Dupuis et al., 2000),
thus underlining the presence of an early and complex mecha-
nism involved in the impairment of the fast anterograde axonal
transport machinery in ALS prior motor neuron degeneration.
From the 76 deregulated genes (25 down and 51 upregulated)
in the spinal cord of 80 days old presymptomatic ALS mice, only
eight genes (Actg1, Adora, Akt1, App, Dctn1, Kif1a, Sirt2, and
Stmn1) or related molecules have been studied in the context
of ALS.
The upregulation ofKif1a is in accordance to previous descrip-
tion (Dupuis et al., 2000) and might represent a regulatory
mechanism in order to compensate the impaired anterograde
transport in neurons. KIF1 is divided into KIF1A, responsible for
transport of synaptic vesicle precursors (Okada et al., 1995), and
KIF1B, described above, a monomeric motor responsible for the
anterograde transport of mitochondria (Nangaku et al., 1994).
Actg1 deregulation described in the spinal cord of 80 days
old ALS mice was already mentioned in a previous ALS publi-
cation (Baciu et al., 2012) and the related actin product of the
gene might impair dendritic spine plasticity with potential impli-
cation to motor neuron toxicity in ALS (Sunico et al., 2011).
Such a mechanism may also involve an impairment of puriner-
gic receptor-mediated actin cytoskeleton remodeling (Goldman
et al., 2013), which is in line with the upregulation of Adora1 tran-
scription codifying adenosine A1 receptor, described in this and
previous studies (Gundlach et al., 1990).
Dctn1 expression was upregulated in presymptomatic spinal
cord (80 days old) of ALS mouse model, thus denoting dyn-
actin impairment as a mechanism in the presymptomatic phase
of the disease. Mutation in Dctn1 gene has been associated to
motor neuron degeneration in ALS (Hafezparast et al., 2003) and
downregulation of the gene was described in residual motor neu-
rons of postmortem material of ALS patients (Jiang et al., 2007).
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Table 3 | List of differentially expressed genes in sciatic nerve of 60 days old SOD1G93A mice related to cytoskeleton.
Probe set ID Gene symbol Gene name Fold change
A_55_P2024808 Abl1 c-abl oncogene 1, receptor tyrosine kinase 1.19
A_52_P489778 Ablim1 actin-binding LIM protein 1 1.30
A_51_P246854 Acta1 actin, alpha 1, skeletal muscle 4.08
A_52_P420504 Acta2 actin, alpha 2, smooth muscle, aorta 2.08
A_55_P1963807 Actg2 actin, gamma 2, smooth muscle, enteric 2.45
A_52_P656699 Actn3 actinin alpha 3 2.81
A_51_P400543 Aif1 allograft inflammatory factor 1 −1.38
A_52_P311297 Als2 amyotrophic lateral sclerosis 2 (juvenile) homolog (human) 1.21
A_55_P1979156 Arap3 ArfGAP with RhoGAP domain, ankyrin repeat, and PH domain 3 1.21
A_52_P195018 Arap3 ArfGAP with RhoGAP domain, ankyrin repeat, and PH domain 3 1.32
A_55_P2047986 Ankrd23 ankyrin repeat domain 23 1.42
A_55_P2021810 Arc activity regulated cytoskeletal-associated protein −1.44
A_52_P153189 Arl2bp ADP-ribosylation factor-like 2 binding protein −1.16
A_55_P2023076 Arpc1b actin related protein 2/3 complex, subunit 1B; Arpc1b −1.63
A_52_P369581 Atm ataxia telangiectasia mutated homolog (human) 1.17
A_52_P400509 Atm ataxia telangiectasia mutated homolog (human) 1.18
A_55_P1980636 Aurka aurora kinase A; Aurka −1.27
A_55_P1983768 Birc5 baculoviral IAP repeat-containing 5 −1.23
A_55_P2029106 Bmf BCL2 modifying factor 1.28
A_51_P357573 Cald1 caldesmon 1 1.18
A_52_P140356 Calm3 calmodulin 3 −1.29
A_66_P106654 Camsap1 calmodulin regulated spectrin-associated protein 1 −1.26
A_55_P2065671 Ccnb1 cyclin B1 −1.60
A_52_P155554 Cdc42ep2 CDC42 effector protein (Rho GTPase binding) 2 −1.24
A_51_P267494 Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3 1.54
A_55_P2043269 Cdc42se1 CDC42 small effector 1 −1.20
A_51_P155142 Cdca8 cell division cycle associated 8 −1.17
A_52_P162099 Ckap2 cytoskeleton associated protein 2 −1.22
A_51_P420547 Clic5 chloride intracellular channel 5 1.32
A_51_P351194 Cnfn cornifelin 1.21
A_51_P109258 Cys1 cystin 1 1.20
A_51_P357085 Dctn6 dynactin 6 1.27
A_51_P335969 Des desmin 1.38
A_55_P2050439 Dlgap5 discs, large (Drosophila) homolog-associated protein 5 −1.42
A_55_P2119907 Dnahc11 dynein, axonemal, heavy chain 11 −1.23
A_52_P485891 Dnahc5 dynein, axonemal, heavy chain 5 −1.20
A_51_P459350 Dstn destrin 1.32
A_55_P2090429 Dync1i1 dynein cytoplasmic 1 intermediate chain 1 −1.43
A_52_P654108 Dync1li2 dynein, cytoplasmic 1 light intermediate chain 2 −1.20
A_51_P203878 Dynll2 dynein light chain LC8-type 2 −1.17
A_51_P203878 Dynll2 dynein light chain LC8-type 2 −1.23
A_55_P2069949 Dynlrb1 dynein light chain roadblock-type 1 −1.22
A_55_P2113673 Eml1 echinoderm microtubule associated protein like 1 −1.23
A_55_P1960097 Epb4.1l3 erythrocyte protein band 4.1-like 3 −1.15
A_55_P1956488 Epb4.9 erythrocyte protein band 4.9 1.26
A_66_P110161 Eppk1 epiplakin 1 1.34
A_51_P440865 Fam110b family with sequence similarity 110, member B 1.19
A_51_P512783 Fam82b family with sequence similarity 82, member B 1.30
A_52_P330395 Farp1 FERM, RhoGEF (Arhgef), and pleckstrin domain protein 1 1.19
A_55_P2029051 Fgd3 FYVE, RhoGEF, and PH domain containing 3 −1.48
A_52_P493620 Fgfr1op Fgfr1 oncogene partner −1.30
A_51_P495379 Fhod1 formin homology 2 domain containing 3 1.31
(Continued)
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Table 3 | Continued
Probe set ID Gene symbol Gene name Fold change
A_55_P2088018 Fhod3 formin homology 2 domain containing 3 −1.27
A_51_P495379 Flna filamin, alpha 1.31
A_55_P2425801 Fmn1 formin 1 1.18
A_55_P2057537 Gas7 growth arrest specific 7 −1.17
A_55_P2025403 Gphn gephyrin 1.14
A_51_P506748 Grlf1 glucocorticoid receptor DNA binding factor 1 −1.26
A_51_P214306 Haus4 HAUS augmin-like complex, subunit 4 1.17
A_51_P440460 Hip1r huntingtin interacting protein 1 related 1.15
A_51_P346445 Hspb7 heat shock protein family, member 7 (cardiovascular) 1.36
A_51_P391445 Ifngr1 interferon gamma receptor 1 1.14
A_55_P1978201 Incenp inner centromere protein −1.29
A_55_P2178044 Inppl1 inositol polyphosphate phosphatase-like 1 −1.34
A_51_P218653 Jph2 junctophilin 2 1.26
A_55_P2008066 Itpr1 inositol 1,4,5-triphosphate receptor 1 1.27
A_51_P400016 Kalrn kalirin, RhoGEF kinase 1.48
A_51_P493857 Katna1 katanin p60 (ATPase-containing) subunit A1 −1.14
A_55_P2184741 Katnal1 katanin p60 subunit A-like 1 −1.29
A_65_P12993 Kif1b kinesin family member 1B −1.40
A_52_P581390 Kif1c kinesin family member 1C 1.35
A_51_P133137 Kif20a kinesin family member 20A −1.27
A_51_P324287 Kif23 kinesin family member 23 −1.23
A_51_P254805 Kif4 kinesin family member 4 −1.19
A_51_P107020 Kif5a kinesin family member 5A 1.25
A_66_P116311 Kif5b kinesin family member 5B −1.20
A_55_P2048937 Kif5c kinesin family member 5C 1.42
A_51_P154753 Klc3 kinesin light chain 3 −1.37
A_52_P410685 Krt7 keratin 7 1.16
A_55_P2086334 Krt85 keratin 85 1.25
A_52_P642801 Lats1 large tumor suppressor −1.23
A_55_P2066613 Lcp1 lymphocyte cytosolic protein 1 −1.18
A_65_P01834 Lima1 LIM domain and actin binding 1 1.18
A_51_P120717 Lmnb1 lamin B1 −1.21
A_55_P2017684 Macf1 microtubule-actin crosslinking factor 1 1.19
A_55_P2009091 Mad1l1 MAD1 mitotic arrest deficient 1-like 1 −1.18
A_55_P2142151 Mapk1ip1 mitogen-activated protein kinase 1 interacting protein 1 1.23
A_55_P1954486 Mapt microtubule-associated protein tau −1.17
A_55_P2004777 Micall2 MICAL-like 2 −1.42
A_51_P124568 Mpp1 membrane protein, palmitoylated 1.54
A_55_P2147280 Myh1 myosin, heavy polypeptide 1, skeletal muscle, adult 2.80
A_55_P1988531 Myh11 myosin, heavy polypeptide 11, smooth muscle 2.35
A_51_P416858 Myl1 myosin, light polypeptide 1 5.53
A_66_P107790 Myl12a myosin, light chain 12A 1.44
A_55_P2107045 Myl4 myosin, light polypeptide 4 1.20
A_51_P308298 Myl9 myosin, light polypeptide 9, regulatory 1.33
A_51_P324303 Mylip myosin regulatory light chain interacting protein −1.18
A_55_P2154049 Myo18a myosin XVIIIA −1.18
A_55_P1955034 Myo1c similar to nuclear myosin I beta; myosin IC 1.20
A_52_P650855 Myo1d myosin ID 1.27
A_55_P2006250 Myo5a myosin VA −1.19
A_66_P115949 Myo9a myosin Ixa −1.15
A_51_P114062 Ncs1 neuronal calcium sensor 1 −1.19
A_55_P2116978 Neb nebulin 1.52
A_52_P367520 Nexn nexilin 1.16
(Continued)
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Table 3 | Continued
Probe set ID Gene symbol Gene name Fold change
A_55_P2423646 Nf2 neurofibromatosis 2 1.21
A_55_P2155582 Nin ninein −1.24
A_55_P2158741 Nos2 nitric oxide synthase 2, inducible −1.26
A_51_P139651 Nos3 nitric oxide synthase 3, endothelial cel 1.55
A_51_P240453 Nusap1 nucleolar and spindle associated protein 1 −1.23
A_55_P2058137 Pde4dip phosphodiesterase 4D interacting protein (myomegalin) 2.21
A_51_P472726 Pdlim2 PDZ and LIM domain 2 1.43
A_52_P579531 Pdlim3 PDZ and LIM domain 3 2.07
A_55_P2004571 Pitpnm2 phosphatidylinositol transfer protein, membrane-associated 2 1.17
A_52_P234729 Pkd2 polycystic kidney disease 2 −1.27
A_52_P668285 Plk4 polo-like kinase 4 −1.19
A_55_P1988083 Prc1 protein regulator of cytokinesis 1 −1.38
A_51_P382152 Procr protein C receptor, endothelial 1.50
A_55_P2429225 Psrc1 proline/serine-rich coiled-coil 1 −1.18
A_51_P455946 Rac3 RAS-related C3 botulinum substrate 3 −1.19
A_55_P2127702 Racgap1 Rac GTPase-activating protein 1 −1.20
A_51_P221337 Ranbp10 RAN binding protein 10 1.16
A_52_P76034 Rcc2 regulator of chromosome condensation 2 −1.18
A_51_P227392 Rhou ras homolog gene family, member U −1.32
A_51_P435922 Rsph9 radial spoke head 9 homolog (Chlamydomonas) −1.44
A_55_P2168628 Sac3d1 SAC3 domain containing 1 −1.14
A_51_P389004 Sgcd sarcoglycan, delta (dystrophin-associated glycoprotein) 1.17
A_51_P115626 Shank3 SH3/ankyrin domain gene 3 1.22
A_52_P78373 Sorbs3 sorbin and SH3 domain containing 3 1.31
A_51_P513530 Spag5 sperm associated antigen 5 −1.28
A_51_P348652 Spast spastin −1.34
A_51_P386870 Sprr2f small proline-rich protein 2F −1.19
A_55_P2081123 Srcin1 SRC kinase signaling inhibitor 1 −0.30
A_55_P1988043 Ssh1 slingshot homolog 1 (Drosophila) −1.15
A_55_P1968977 Stk38l serine/threonine kinase 38 like −1.19
A_52_P639064 Strbp spermatid perinuclear RNA binding protein −1.23
A_51_P123676 Synpo synaptopodin 1.19
A_55_P2004801 Tacc3 transforming, acidic coiled-coil containing protein 3 −1.18
A_51_P429276 Tmod3 tropomodulin 3 1.36
A_55_P2008895 Tmsb15b1 thymosin beta 15b1 1.41
A_52_P315976 Tpm2 tropomyosin 2, beta 2.00
A_55_P2121408 Tpm2 tropomyosin 2, beta 2.29
A_51_P369200 Tpx2 TPX2, microtubule-associated protein homolog (Xenopus laevis) −1.20
A_51_P208697 Ttl tubulin tyrosine ligase −1.43
A_66_P119518 Tuba8 tubulin, alpha 8 −1.24
A_51_P514256 Tubb2b tubulin, beta 2B class IIB −1.34
A_55_P2034864 Tubb2b tubulin, beta 2B class IIB −1.32
A_55_P2013645 Tubg2 tubulin, gamma 2 1.17
A_51_P226932 Tubgcp2 tubulin, gamma complex associated protein 2 1.18
A_52_P484405 Twf1 twinfilin, actin-binding protein, homolog 1 (Drosophila) −1.15
A_52_P190973 Vcl vinculin 1.25
A_55_P1963443 Vps18 vacuolar protein sorting 18 (yeast) 1.17
Each Arap3, Atm, Dynll2, Tpm2, and Tubb2b have been demonstrated in the list by two different Probes Set IDs.
There is a lack of information on dynactin regulation before clin-
ical onset of ALS despite the fact that dynein-dynactin complex,
the only retrograde transport motor, contributes to formation of
SOD1 inclusions in the disease (Strom et al., 2008). Furthermore,
deregulation of Schwann cell genes related to neurothropin-
dependent mechanisms in association to an impaired axonal
transport may enhance motor neuron vulnerability in ALS (Koh
et al., 2005; Niewiadomska et al., 2011).
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FIGURE 4 | Venn diagram of differentially expressed genes related
to cytoskeleton analysis in spinal cords (40 and 80 days) and
sciatic nerve (60 days) of SOD1G93A animals compared to
wild-type controls by means of microarray experiments. The
enrichment cytoskeleton lists were obtained by means of DAVID
tool based on Cellular Component Ontology, which identified 146
differentially expressed genes in the sciatic nerve from 60 days old
mice, 76 genes in spinal cord from 80 days old mice and 14 genes in
spinal cord from 40 days old mice. Venn diagram demonstrated nine
genes common between sciatic nerve and 40 days old mouse spinal
cord, 10 genes common between sciatic nerve and 80 days old mouse
spinal cord, and only one gene common between spinal cord groups.
Positive (+) and negative (−) signals represent the upregulated and the
down regulated genes, respectively.
The upregulation of Sirt2 expression in the spinal cord of
80 days old mice might trigger toxicicity to motor neurons in
the late stage of the presymptomatic age by increasing deacety-
lation of alfa tubulin (Korner et al., 2013; Taes et al., 2013).
Moreover, the upregulation of Stmn1 in the ALS spinal cord
before neuronal death is in agreement to previous description
on stathmin protein accumulation in spinal cord motor neurons
leading to Gogi apparatus fragmentation and collapse of micro-
tubule network (Strey et al., 2004). Furthermore, the formation
of perikaryal/axonal intermediate filament inclusions, neurofil-
ament abnormalities and genetic defects in microtubule-based
transport that may facilitate the elevation of the toxic amyloid
beta precursor in ALS (Spadoni et al., 2009; Bryson et al., 2012)
might correlate the downregulation of App seen in the spinal cord
of 80 days presymptomatic phase to a neuroprotective regulation
before the neuronal death onset.
Finally, the downregulation of Vapa in the spinal cord of 80
days old ALS mice is also an original and interesting finding of
the present analysis. VAMP/synaptobrevin-associated proteins A
and B (VAPA and VAPB) are both enriched on endoplasmic retic-
ulum and Golgi membranes and are capable to interact with
cytoskeleton elements in order to maintain the organelle mor-
phology (Nishimura et al., 1999). Despite a lack of information
on VAPA function in the central nervous system, VAPB mutation
is associated to a familial form of ALS (Nishimura et al., 2004).
It should be pointed out the regulation Maea, the unique gene
that was overexpressed in the spinal cord of both 40 and 80
days old ALS mice, indicating its long lasting involvement in the
presymptomatic events in the ALS spinal cord. The role of Maea
in ALS is unknown but it could participate in the immunomod-
ulatory signaling of non-neuronal cells-induced toxicity in ALS
(Levine et al., 1999; McGeer and McGeer, 2002; Pasinelli and
Brown, 2006).
From the 146 deregulated genes (74 down and 72 upregulated)
in the sciatic nerve of 60 days presymptomatic old SOD1G93A old
mice, only 10 genes or related molecules have been studied in
context of ALS.
The downregulation of the Aif1, Ccnb1, and Mapt in the
presymptomatic ALS mice is likely to participate in the early
events in the ALS peripheral nerve pathology. Aif1 encodes
the allograft inflammatory factor-1 (AIF-1) and AIF-1 positive
microglia/macrophages are among the earliest cells to respond
to nerve injury (Schwab et al., 2001). It is likely that AIF-1 may
act as an initiator of the early microglial/macrophage-induced
immunomodulation leading a motor axon retraction and neu-
romuscular junction disruption before neuronal degeneration
(Dibaj et al., 2011). Furthermore, Ccnb1 deregulation-induced
cytoskeleton disorganization (Husseman et al., 2000) and also
altered neuronal cytoskeleton protein Tau encoded by Mapt -
induced microtubule stabilization and assembly deregulation
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FIGURE 5 | Graphs show relative fold change values for Kif1b in
SOD1G93A (TG) and age matched wild-type controls (WT) mice by
means of qPCR. Gene expression differences in the spinal cord [40 days
old, (A)], sciatic nerve [60 days old, (B)] and microdissected motor neurons
[40 days old, (C)] are pointed. Kif1b expression was downregulated in
sciatic nerve Schwann cell [60 days old, (D)] enriched samples from
microdissection, flow cytometry sorting and cell culture procedures.
Means ± SEM from four samples of each group. ∗ and ∗∗ p-values, < 0.05
and < 0.01, respectively, according to unpaired t test.
(Aronov et al., 2002) are possible mechanisms related to early
axonal retraction taking place in presymptomatic phases of the
disease (Aronov et al., 2002).
Actn3, Als2, Kif5a, Kif5c, Nos3, and Tmod3 were found upreg-
ulated in the sciatic nerve of 60 days old presymptomatic ALS
mice and their related molecules have been mentioned in the
context of ALS mechanisms. ACTN3, one of the four human
alpha-actinin isoforms, has been associated to ALS progression
in human muscle (Pradat et al., 2012; Bernardini et al., 2013).
Moreover, the upregulated Tmod3, which codifies the tropomod-
ulin (TMOD), an actin-capping protein for the slow-growing end
of filamentous actin (Ito et al., 1995), may represent a need for
the dynamic polymerization of actin cytoskeleton, probably in
the Schwann cells of ALS nerve. Interestingly, the mutation of
ubiquitously expressed TMOD3 protein is responsible for type 5
familial ALS (Cox and Zoghbi, 2000). Furthermore, despite ALS2
deficiency accounts for ALS2 familial form (Hadano et al., 2001;
Yang et al., 2001), the upregulation of Als2 seen in the 60 days
old presymptomatic ALS sciatic nerve could reflect a transient
Schwann cell neuroprotective paracrine response (Hadano et al.,
2010). In fact, ALS2/alsin, a guanine nucleotide exchange factor
for GTPase Rab5, is involved in endosome fusion/trafficking, neu-
rite outgrowth and corticospinal axon integrity (Deng et al., 2007;
Lai et al., 2009), probably by interfering with the accumulation of
immature vesicles and misfolded proteins (Lai et al., 2009).
We have also found a deregulation of the Nos2 and Nos3
expression in sciatic nerve of 60 days old ALS mice, with-
out changes in presymptomatic spinal cord. The synthesis of
inducible NOS in the spinal cord and peripheral nerve of ALS
model in the presymptomatic phase of the disease has been
mentioned (Almer et al., 1999; Chen et al., 2010).
Important finding of the present study was also the regula-
tion of several genes of kinesin molecules in the sciatic nerve
of 60 days old presymptomatic ALS mice. The differential Kif5
regulation in the sciatic nerve observed in our microarray anal-
ysis may in fact represent the gene regulation in the Schwann
cells where the KIF5 participate in the myelin integrity (Bolis
et al., 2009). In this context, KIF5B might be of substantial
interest because it also expresses in non-neuronal cells and
its regulation/activity has not been explored in ALS mecha-
nisms. Further evidence for KIF5 mechanisms in non-neuronal
cells were obtained from the absence of Kif5 expression in the
spinal cord of presymptomatic SOD1G93A mice by gene profiling
study (this work) and qPCR analysis (Kuzma-Kozakiewicz et al.,
2013).
TOPOGRAPHIC AND CELLULAR MODULATION OF Kif1b OF KINESIN
FAMILY
The downregulation of Kif1b in the sciatic nerve showed by
microarray and qPCR was in the opposite direction to the upreg-
ulation of the gene seen in the spinal cord of presymptomatic
ALS mice. Importantly, only the Kif1b was deregulated in the two
evaluated regions and also was reported previously in the context
of ALS (Ferraiuolo et al., 2007; Kuzma-Kozakiewicz et al., 2013).
Furthermore, it is the first time Kif1b expression or its protein has
been described in Schwann cells. The development of technology
to enrich Schwann cells allowed the present analysis.
Kif1b deregulation in presymptomatic ALS seems to be an
important event, specially in the Schwann cells because KIF1B
is required for adequate myelination process by oligodendrocytes
(Lyons et al., 2009). Presently, myelin pathology is not clear in
ALS peripheral nerves (Heads et al., 1991). Nonetheless, it is still
undefined whether peripheral myelin morphological alteration in
ALS is a consequence of axonal degeneration (Perrie et al., 1993).
There is a lack of information on myelin alterations in periph-
eral nerves of presymptomatic ALS mice and it is uncertain
whether impairments in the Schwann cell function could con-
tribute to ALS axonal pathology and dying back events. That is
actually an important issue in the pathogenic mechanism of the
disease because myelin cell function overtakes action potential
conduction along peripheral axons (Monk and Talbot, 2009). In
fact, the control of axoplasmic Ca2+ and posttranslational mod-
ifications of local trafficking proteins are part of trophic support
signaling provided by myelinating cells. We might speculate that
an impaired crosstalk between Schwann cell and motor axon in
presymptomatic stages of the disease could trigger axonal retrac-
tion and Wallerian degeneration (Lyons et al., 2009; Kiryu-Seo
and Kiyama, 2011; Gentil and Cooper, 2012).
The above discussion indicates the importance to evaluate the
events in specific cell types notably in the context of peripheral
nerve-induced neuropathology in ALS, because a differential reg-
ulation can occur specifically in Schwann cells and also altered
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axonal transport might modify the local traffic of RNAs (Ticozzi
et al., 2010).
Single cell laser microdissection has been employed by our
group and other researchers to evaluate gene expression on
enriched cell types (Ferraiuolo et al., 2007; DeOliveira et al., 2009;
Guipponi et al., 2010; Kudo et al., 2010; Tanaka et al., 2012). We
have developed and showed here for the first time the method
to immunolabel mouse Schwann cells and motor neurons and
also the procedures to enrich cell samples for molecular analy-
ses by means of single cell laser microdissection. We have also
developed and demonstrated in this work the methodology to
enrich mouse Schwann cells by means of primary cell culture and
cell sorting. We still do not know precisely the limitations of the
enrichment techniques employed here. Nevertheless, it should be
emphasized the agreement of the results obtained by the different
methods.
It is of substantial importance that the methodology allowed
the observation of a differential regulation of Kif1B in the
enriched ChAT immunolabeled motor neurons (upregulation)
and Schwann cells (downregulation). The results were coinci-
dent to those obtained in qPCR and microarray analyses of whole
spinal cord and sciatic nerve of presymptomatic ALS mice.
A differential gene regulation in specific cell types in a neu-
roglial unit, the motor neuron-Schwann cell unit in this case,
highlights the complexity of cellular and molecular mechanisms
of ALS, remarkably before clinical onset. Kif1b upregulation in
immunolabeled motor neurons was in line to a previous work
that employed toluidine blue-enriched putative motor neurons
of presymptomatic ALS mice (Ferraiuolo et al., 2007). This find-
ing indicates an involvement of a motor protein of kinesin family
in the axonal trafficking before the death of motor neurons and
the appearance of neurological symptoms. The elevation of the
protein in ALS neurons might be a substrate for an increased
kinesin-1 phosphorylation and a diminution of kinesin-1 func-
tion with a subsequent defect of fast axonal transport (Morfini
et al., 2013).
The Kif1b downregulation in the sciatic nerve and also in the
enriched Schwann cells of presymptomatic ALS mice is a major
original contribution of the present work. The recent descrip-
tion on the role of KIF1B for the adequate function of central
myelinating cells (Lyons et al., 2009; Gentil and Cooper, 2012)
opens up the possibly for the existence of KIF1B mechanisms
in the paracrine trophic actions of Schwann cells to peripheral
motor neurons. Deregulated KIF1B in Schwann cells highlights
the possibility of no autonomous cell toxicity of Schwann cells
to motor neurons in ALS, mechanisms that should be investi-
gated in details in future works. In fact, the non-autonomous
cell toxicity of central glia to motor neurons has been described
(Boillee et al., 2006a) and the related molecular pathways are
under investigation.
In conclusion, the present work demonstrated cytoskeleton
gene regulation as an important occurrence inmotor neurons and
Schwann cells in the presymptomatic stages of ALS and may be
of importance in the dying back mechanisms of neuronal death
in the neurodegenerative disease. The differential regulation of
Kif1b in the spinal cord (upregulation) and sciatic nerve (down-
regulation) was coincident to that found in the enriched motor
neurons and Schwann cells and emerged as an important event in
the pathogenic mechanism of ALS.
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